Clinical Application of Intravenous New Castle Disease Virus - HUJ Oncolytic Virus in the Treatment of Advanced Glioblastoma Multiforme, Soft and Bone Sarcomas and Neuroblastoma Patients, Resistant to Conventional Anti- Cancer Modalities

Patients with specific metastatic cancers who failed prior therapeutic regimes will be treated with NDV for at least a year or until disease progression. The study will measure progression-free disease and posits that it will be extended.

Start Date01 Jul 2011

Sponsor / Collaborator

Hadassah University Hospital

100 Clinical Results associated with New Castle Disease Virus(Hadassah University Hospital)

100 Translational Medicine associated with New Castle Disease Virus(Hadassah University Hospital)

100 Patents (Medical) associated with New Castle Disease Virus(Hadassah University Hospital)

Literatures (Medical) associated with New Castle Disease Virus(Hadassah University Hospital)

01 Oct 2012·Tropical Animal Health and ProductionQ3 · AGRICULTURAL & FORESTRY SCIENCE

Effect of feeding different levels of energy and protein on performance of Aseel breed of chicken during juvenile phase

Q3 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Rudra Nath Chatterjee ; Mattam Niranjan ; Arun Kumar Panda ; Ullengala Rajkumar ; Santosh Haunshi ; Mahendra Kumar Padhi

A study was conducted to evaluate the effect of feeding different metabolizable energy (ME) and crude protein (CP) levels on performance of Aseel chicken during 0 to 8 weeks of age (Juvenile phase). At 1 day old, 432 chicks were randomly distributed into nine groups. Each group had 48 chicks distributed into eight replicates with six birds in each. Maize-soybean meal-based diets with three ME levels (2,400, 2,600 and 2,800 kcal/kg) and three CP levels (16%, 18% and 20%) were fed to birds in a 3 × 3 factorial design. Different ME levels had significant effect on body weight gain (BWG), feed intake and feed conversion ratio (FCR). Birds fed diet with 2,400 kcal/kg ME had significantly lower BWG (P < 0.004), lower shank length (P < 0.0007), higher feed intake (P < 0.0001) and poor FCR (P < 0.0001) than those fed diet with either 2,600 or 2,800 kcal/kg ME. Energy efficiency ratio was not influenced by ME, CP or their interaction. However, protein efficiency ratio was significantly higher at higher ME levels and lower at higher CP levels. There was significant effect of ME, CP and their interaction on serum protein and cholesterol levels. However, they made no significant effect on antibody titre against New Castle disease vaccine. The study concluded that provision of 2,600 kcal/kg ME and 16% CP would be ideal for optimum growth of Aseel birds during juvenile phase. However, to obtain better FCR, feeding Aseel birds with diet having 2,800 kcal/kg ME and 16% CP would be ideal.

100 Deals associated with New Castle Disease Virus(Hadassah University Hospital)

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

New Castle Disease Virus(Hadassah University Hospital)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation